Phase Ib, Open-Label, Multicenter, Doseescalation Study followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of Ro5479599, a Glycoengineered Antibody Against Her3, Administered in combination with Pertuzumab and Paclitaxel

Cancer type: Breast cancer

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, HER3 antibody

Status: Completed

Link to